Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹481 Cr
P/E Ratio
15.3
P/B Ratio
2.93
Industry P/E
35.02
Debt to Equity
0
ROE
19.43 %
ROCE
26.28 %
Div. Yield
1.41 %
Book Value
372.21
EPS
71.17
CFO
₹124.54 Cr
EBITDA
₹230.47 Cr
Net Profit
₹175.20 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Jenburkt Pharma
| -10.35 | 9.44 | -9.27 | 47.39 | 20.90 | 26.14 | 10.73 |
|
BSE Healthcare
| -5.48 | 1.35 | 0.22 | 22.74 | 20.05 | 23.06 | 9.77 |
|
BSE Small Cap
| -10.07 | 4.18 | -3.21 | 7.10 | 18.99 | 35.87 | 15.84 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Jenburkt Pharma
| 79.01 | 4.64 | 21.95 | 25.96 | 8.73 | -30.80 | -7.13 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 737.00 | 6,679.32 | 26.79 | 13.8 | |
| 2,202.50 | 9,011.72 | 74.24 | 12.96 | |
| 416.90 | 5,141.64 | 68.95 | 6.24 | |
| 913.45 | 5,221.77 | 40.99 | 14.76 |
No Review & Analysis are available.
Jenburkt Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical formulations primarily in India. It offers products in various therapeutic areas, such as pain management, neuropathic pain, anthelmintics, analgesics and... antipyretics, anti-arthritic, anti-diabetic, anti-infective, anti-fungal, anti-malarial, anti-ulcerant/antacid, aphrodisiac, cough and cold, and muscle relaxants, as well as nutraceutical and consumer products. The company provides its products through stockists and super stockists to doctors, chemists, large government and semi-government institutions, missionary hospitals, public sector enterprises, etc. It also exports its products to approximately 13 countries. The company was founded in 1985 and is based in Mumbai, India. Read more
Incorporated
1985
Chairman
Ashish U Bhuta
Managing Director
Ashish U Bhuta
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Jenburkt Pharmaceuticals Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Jenburkt Pharmaceuticals Ltd stood at ₹ 181 Cr as on 31-Dec-24
The share price of Jenburkt Pharmaceuticals Ltd is ₹1,089.00 (BSE) as of 23-Apr-2025 IST. Jenburkt Pharmaceuticals Ltd has given a return of 20.9% in the last 3 years.
Jenburkt Pharmaceuticals Ltd has a market capitalisation of ₹ 481 Cr as on 23-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Jenburkt Pharmaceuticals Ltd is 2.93 times as on 23-Apr-2025, a 22% discount to its peers’ median range of 3.75 times.
The P/E ratio of Jenburkt Pharmaceuticals Ltd is 15.30 times as on 23-Apr-2025, a 56% discount to its peers’ median range of 35.02 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Jenburkt Pharmaceuticals Ltd and enter the required number of quantities and click on buy to purchase the shares of Jenburkt Pharmaceuticals Ltd.
Jenburkt Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical formulations primarily in India. It offers products in various therapeutic areas, such as pain management, neuropathic pain, anthelmintics, analgesics and antipyretics, anti-arthritic, anti-diabetic, anti-infective, anti-fungal, anti-malarial, anti-ulcerant/antacid, aphrodisiac, cough and cold, and muscle relaxants, as well as nutraceutical and consumer products. The company provides its products through stockists and super stockists to doctors, chemists, large government and semi-government institutions, missionary hospitals, public sector enterprises, etc. It also exports its products to approximately 13 countries. The company was founded in 1985 and is based in Mumbai, India.
The prominent promoters of Jenburkt Pharmaceuticals Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
BHUTA HOLDINGS PRIVATE LIMITED |
13.96%
|
|
JAYSHREE UTTAM BHUTA |
12.16%
|
|
KALINDI HEMENDRA Bhuta |
9.06%
|
|
ASHISH UTTAM BHUTA |
5.92%
|
The chairman of the company is Ashish U Bhuta, and the managing director is Ashish U Bhuta.
There is no promoter pledging in Jenburkt Pharmaceuticals Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,512
|
|
|
6,653
|
|
|
5,320
|
|
|
5,217
|
| Jenburkt Pharmaceuticals Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
20.75
|
|
Operating margin(%)
|
24.64
|
|
Net Margin(%)
|
20.2
|
|
Dividend yield(%)
|
1.41
|
Yes, TTM profit after tax of Jenburkt Pharmaceuticals Ltd was ₹31 Cr.
₹-19.05
(
